Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus
Launched by SHAARE ZEDEK MEDICAL CENTER · Jan 8, 2014
Trial Information
Current as of June 27, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. History of pruritus of \>8 weeks duration.
- • 2. Severity score of pruritus ≥5 as defined by VAS
- • 3. Discontinuation of any medication with presumed antipruritic effects at least 1 week before the study (including Calmmax cream)
- • 4. Negative pregnancy test result for all participating women of childbearing age;
- Exclusion Criteria:
- • 1. Known allergy to Calmmax cream
- • 2. Any acute illness
- • 3. Liver cirrhosis
- • 4. Active dermatological disorder other than UP
- • 5. Decompensated heart failure
- • 6. Inability to give informed consent
- • 7. Known poor adherence to medical recommendations
About Shaare Zedek Medical Center
Shaare Zedek Medical Center, a leading healthcare institution located in Jerusalem, Israel, is dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in medical services, the center integrates cutting-edge technology with compassionate healthcare practices. With a multidisciplinary team of experienced researchers and clinicians, Shaare Zedek actively participates in various clinical trials aimed at exploring new treatments and therapies across multiple medical disciplines. The center prioritizes patient safety, ethical standards, and scientific rigor, ensuring that all research conducted aligns with the highest benchmarks of clinical excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Itzchak Slotki, MD
Principal Investigator
Shaare Zedek Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials